A Potential Therapeutic Target in Autoimmune Diseases
Interleukin 33 (IL-33) is a newly described member of the IL-1 superfamily of cytokines. Through activation of the ST2 receptor, which is widely expressed particularly by helper T 2 cells and mast cells, IL-33 is involved in T-cell–mediated immune responses. Many previous studies have demonstrated that IL-33 may have a pleiotropic function in different diseases, and it could represent a novel target for the treatment of a range of diseases. Recent works have explored the role of IL-33 in chronic autoimmune diseases, such as systemic sclerosis, inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus. These results indicate that IL-33 may contribute to the pathogenesis of chronic autoimmune diseases. Hence, in this review, we discuss the biological features of IL-33 and summarize recent advances on the role of IL-33 in the pathogenesis and treatment of autoimmune diseases.
- therapeutic target
- autoimmune diseases
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.